Charles River Laboratories (CRL) Tops Q2 EPS by 32c, Lifts Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $351.87 --0%
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.58, $0.32 better than the analyst estimate of $1.26. Revenue for the quarter came in at $682.6 million versus the consensus estimate of $641.63 million.
GUIDANCE:
Charles River Laboratories sees FY2020 EPS of $7.05-$7.35, versus the consensus of $6.91.
- Revenue growth, reported 7.5% – 9.0%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Charles River Laboratories (CRL) Tops Q3 EPS by 12c ; Offers Guidance
- Peabody Energy (BTU) Misses Q3 EPS by 28c
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
